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Abstract
Background
In vitro diagnostic (IVD) investigations are indispensable for routine patient management.
Appropriate testing allows early-stage interventions, reducing late-stage healthcare expen-
diture (HCE).
Aim
To investigate HCE on IVDs in two developed markets and to assess the perceived value of
IVDs on clinical decision-making. Physician-perceived HCE on IVD was evaluated, as well
as desired features of new diagnostic markers.
Methods
Past and current HCE on IVD was calculated for the US and Germany. A total of 79 US/Ger-
man oncologists and cardiologists were interviewed to assess the number of cases where:
physicians ask for IVDs; IVDs are used for initial diagnosis, treatment monitoring, or post-
treatment; and decision-making is based on an IVD test result. A sample of 201 US and
German oncologists and cardiologists was questioned regarding the proportion of HCE
they believed to be attributable to IVD testing. After disclosing the actual IVD HCE, the phy-
sician’s perception of the appropriateness of the amount was captured. Finally, the associa-
tion between physician-rated impact of IVD on decision-making and perceived contribution
of IVD expenditure on overall HCE was assessed.
Results
IVD costs account for 2.3% and 1.4% of total HCE in the US and Germany. Most physicians
(81%) believed that the actual HCE on IVDs was >5%; 19% rated the spending correctly
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(0–4%, p<0.001). When informed of the actual amount, 64% of physicians rated this as
appropriate (p<0.0001); 66% of decision-making was based on IVD. Significantly, more
physicians asked for either additional clinical or combined clinical/health economic data
than for the product (test/platform) alone (p<0.0001).
Conclusions
Our results indicate a poor awareness of actual HCE on IVD, but a high attributable value of
diagnostic procedures for patient management. New markers should deliver actionable and
medically relevant information, to guide decision-making and foster improved patient
outcomes.
Introduction
In vitro diagnostic (IVD) testing has become an indispensable tool in clinical practice for diag-
nosing and monitoring of diseases, as well as providing prognosis and predicting treatment
response [1, 2]. In addition, IVD is used to assess the potential risk of developing a disease or
disorder and to guide patient management [1]. IVD of analytes originating from body speci-
mens, including blood and tissue biopsies, is used alone or in combination with clinical investi-
gations [2] and is perceived as an important tool for high-quality medical outcomes [3]. There
are over 40,000 different IVD products available that provide information to doctors and
patients on a huge range of conditions. These comprise markers for inorganic chemistry (elec-
trolytes, toxins, and heavy metals), markers for organic chemistry/biochemistry (proteins, lip-
ids, and carbohydrates), as well as molecular biologic procedures (sequencing and polymerase
chain reaction). One German study revealed that up to 187 of 584 diagnoses can be confirmed
exclusively by an IVD testing [4]. Routine diagnostics and population screening programs,
such as the Pap smear for cervical carcinoma, have the potential to identify high-risk individu-
als and to prevent disease onset or progression [5, 6]. The introduction of cervical cancer
screening programs in Europe has led to a substantial decrease in mortality [7, 5]. Furthermore,
timely IVD testing allows more early-stage and cost-effective interventions, instead of
advanced-stage therapy, which is generally associated with worse prognosis and a higher use of
healthcare resources [8, 9].
A New Trend towards Companion Diagnostics
The contemporary concept of companion diagnostics is based on identifying patients with a
high likelihood of response to a specific drug, hence curbing total costs of healthcare due to tar-
geted patient management. A well-known example is Herceptest1–the companion diagnostic
for HER2-positive breast cancer and gastric cancer–which identifies patients eligible for trastu-
zumab treatment [10]. Other examples of Food and Drug Administration (FDA)-approved
drugs with companion diagnostics include cetuximab, imatinib, and vemurafenib, which are
used to treat metastatic colorectal cancer, gastrointestinal stroma tumor, and late-stage mela-
noma, respectively [11, 12] With the emergence of new molecular technologies identifying
tumor aberrations that can be treated with targeted agents, the number of companion diagnos-
tic tests used in oncology will significantly increase in the future.
Companion diagnostics has the potential to enable the selection of the correct drug dose at
the appropriate time of a patient`s treatment course, thereby reducing overall therapy cost.
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The investment of developing companion diagnostic drugs is substantial, however [13]. This is
particularly true for immunotherapy treatments, such as those targeting cytotoxic T-lympho-
cyte antigen 4 (CTLA-4), programmed cell death-1 (PD-1), or programmed cell death 1 ligand
1 (PD-L1). For example, the cost of using the PD-1 inhibitor pembrolizumab has already
exceeded an annual cost per patient of US$1 million [13]. In an initiative to help manage costs
while maintaining high quality care, the American Society of Clinical Oncology (ASCO) has
recently proposed a framework to assess the value of cancer treatment options [14].
Value in Healthcare
The question of how to measure value in healthcare has been discussed controversially. None-
theless, there is agreement on the overarching concept of assessing health outcomes achieved
per dollar spent [15]. In economic terms, the value component would equal clinical utility and
cost-effectiveness [16]. The value term simultaneously involves patients (utility and efficacy)
and payers (efficiency), describing a framework for performance improvement in healthcare
[17]. The Joint Commission of Healthcare Organizations has defined the value term as “the
degree to which patient care services increase the probability of desired patient outcomes and
reduce the probability of undesired outcomes, given the current state of knowledge” [18].
The Value of IVD
IVD tests have been under increasing cost pressure over the last decade as a result of their
increasing use and concerns about uncontrollable healthcare expenditures [19]. Furthermore,
the diagnostic industry is now facing stricter regulatory hurdles for product approval [20]. For
many years, registration of diagnostic tests in the European Union only required the CE label;
however, in the light of financial shortfalls, health authorities are increasingly requesting proof
that diagnostic tests not only have reasonable pricing, but also add considerable value to society
[21].
Many articles introduce frameworks of how best to assess the value of laboratory diagnostics
[22, 23]. Basically, IVD value may be defined as:
IVD value ¼ Performance  Efficiency
IVD value ¼ ½Technical accuracy=Turnaround time  ½Utility=Costs
Performance is mandated to give the highest accuracy, referring to outcome reliability and
reproducibility, with the lowest turnaround time. Efficiency is derived from the percentage of
confident clinical decisions made (clinical utility) over costs. While costs refer to resource
usage for a given process [24], utility speaks to driving the most accurate conclusion given
available evidence for a diagnostic test [25].
While the performance of IVD testing devices is fairly comparable across the diagnostic
industry, the efficiency component is the main differentiator and determines the medical value
component. Although the utility–cost relationship is difficult to assess, it is important to quan-
tify this amount and to estimate the current value of IVD testing in proportion to its cost rela-
tive to overall healthcare expenditure (HCE).
Aims. In 2005, a report by the Lewin Group revealed that diagnostics comprise less than
5% of hospital costs and approximately 1.6% of all Medicare costs, while accounting for 60–
70% of clinical decisions [26]. However, the authors do not provide citable references for their
claims. The main objective of this study was to find statistical backing for the surprising util-
ity–cost ratio.
IVD Testing in Medical Practice: A Status Report
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Methods
This study was conducted in three stages: literature review, interviews with medical oncologists
and cardiologists, and a confirmatory internet-based multiple-choice survey (SERMO). Given
that the study was based on interview responses and did not involve active treatment of human
participants, it was not necessary to include an institutional review board (ethics committee).
Table 1 provides an overview of all stages of the study.
Stage 1
A literature review was conducted to assess the total percentage of HCE on IVDs in two coun-
tries–the US and Germany. Data for healthcare and diagnostic expenditures were derived from
government and private industry sources. Secondary sources were assessed for information
and data on IVD HCE including government websites, healthcare agencies, industry, and
Table 1. Study Design.
Study
Stage
Quality Objectives/Aims Methods Countries Physicians
Stage 1 Quantitative • % of healthcare expenditures used
for IVD
Systematic
literature research
Germany and US None
• % of healthcare expenditures used
for IVD in hospital and private
practice
Stage 2 Qualitative &
Quantitative
• Patients seen per week Interviews Germany Onc (N = 20) Card (N = 20
• Distribution US Onc (N = 20)
 New patients Card (N = 19)
 Patients undergoing treatment
 Patients in post-treatment
phase
• Overall and speciﬁc amount of IVD
testing
 In initial diagnostic phase
• IVD subtype use
• Rated importance of IVD
subtype
 In treatment phase
 In post-treatment follow-up
• Treatment decision based on IVD-
testing
Stage 3 Quantitative • % of healthcare expenditures used
for IVD
Questionnaire Germany Onc (N = 30) Card (N = 51)
• Perceived HCE on IVD testing US Onc (N = 70) Card (N = 50)
• Perception of spending
appropriateness
• Design of optimal biomarker Germany, US, UK,
Canada, Norway,
Switzerland
Onc (N = 102) Card (N = 102)
GP (N = 38) Int. M (N = 38) Path
(N = 68)
Display of study design, objectives and methods used in the three different parts of the analysis. Number of sources, included physicians, their
specializations and country of origin.
IVD, in-vitro diagnostic; Onc, oncologist; Card, cardiologist; GP, general practitioner; Int. M, internal medicine; Path, pathologist; HCE, healthcare
expenditure.
doi:10.1371/journal.pone.0149856.t001
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market reports. Various search terms were used to ascertain IVD spending data, including
“clinical laboratory industry revenues”, “in-vitro diagnostic spending”, “clinical laboratory
market”, and “reimbursement for clinical laboratories”.
Data for total US HCE for the period 1993–2011 were derived from the Centers for Medi-
care and Medicaid Services [27]. At the time of this analysis, 2009–2013 data for IVD expendi-
ture in the US had not yet been published, therefore an estimate for spending during that
period was made based on an average annual growth rate of 4% [28]. For the years 1994–1997,
an average growth rate of 5.3% was applied. The 1993 IVD spending was an estimate based on
the ratio of IVD manufacturers’ revenues over total IVD spending in other years.
For Germany, both total government healthcare spending and IVD spending were captured
from the Federal Statistical Office [29]. All calculations were based on German government
HCE, which accounts for about 77% of overall healthcare costs [30].
The percentage of total healthcare spending on IVDs was calculated by dividing the total
IVD spending by the total HCE.
Selection of Countries. The US and Germany were selected as they represented approxi-
mately the estimated global HCE in 2009 [31] and therefore provide satisfactory proxies for
other countries in developed markets. Fig 1 displays the percentage of GDP allocated to HCE
and the total HCE split according to payers for both countries in 2013.
Stage 2
Interviews were conducted with medical oncologists and cardiologists in the US and Germany.
The interview was designed to assess (i) the number of patients seen per week and (ii) the dis-
tribution of patients according to treatment stages. Furthermore we assessed (iii) in how many
Fig 1. Percentage of public and private HCE of GDP (pie) in the US and Germany in 2013. Thin lines,
public HCE; bold lines, private HCE without out-of-pocket; black fill, out-of-pocket HCE; white fill, rest of GDP
(non-HCE) HCE, healthcare expenditure; GDP, gross domestic product; $B, US$ billion.
doi:10.1371/journal.pone.0149856.g001
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cases physicians were asking for IVD and (iv) in how many cases IVD was used for either initial
diagnosis, treatment monitoring or post-treatment follow up. With this in mind we also ana-
lyzed which IVD subtypes were used frequently during initial patient work up and how impor-
tant these subtypes were rated by physicians. We then investigated (v) in how many cases a
treatment decision (defined as stopping, initiating or continuing treatment) is based on IVD-
test results.
Interviews were conducted by three neutral researchers (all male; one MD, one PhD, and
one BS, MBA) employed by the Enterprise Analysis Corporation (EAC; Stamford, CT, US).
Interviewers had a strong knowledge of diagnostics testing and were experienced in conducting
interviews with physicians, laboratory workers and other healthcare professionals.
Participants were contacted by telephone and asked to participate in the study; the nature of
the study was briefly described and an honorarium was offered for participation. Interviewers
had no prior relationship with physicians. Physicians were required to see20 patients per
week in their practice. These interviews took place by phone and were scheduled to take 1
hour; no non-participants were involved in the interviews. A pilot-tested, structured interview
was conducted. Interview questions were not shared with the physician in advance of the inter-
view. There were no repeat interviews. In general, interviews were not recorded although some
may have been if the physician consented to recording. Notes were taken during the interview;
additional comments and notes were added to the interview protocol directly after the inter-
view whilst fresh in the mind of the interviewer. Transcripts were not returned as there were
few open-ended questions and transcripts were not lengthy.
Data from the interviews were entered into a database (Microsoft Access) by one person;
this was reviewed for accuracy by a project manager at EAC.
Stage 3
This stage involved a confirmatory internet-based multiple-choice survey of physician, the pur-
pose of which was (vi) to assess how much physicians believed to be spent on IVD testing and
to compare their assumption with the actual HCE spent on IVD calculated in Stage 1 and (vii)
to assess, after disclosing the actual HCE on IVDs, if physicians felt this amount was appropri-
ate. Finally, the perceived value of IVDs was correlated with the physician’s estimated cost.
Stage 3 was executed using SERMO, an anonymized internet-based multiple-choice survey,
executed by Genentech (South San Francisco, CA, US), hosted by WorldOne (Boston, MA,
US). SERMO is a shared service, with a facility that allows multiple companies to gain quick
and comprehensive insights on conceptual questions via physician surveys. Interested physi-
cians apply to take part in surveys and receive questions from several companies. Invitations to
participate in this cross-sectional survey were sent to physicians from the US, UK, Germany,
Canada, Norway, and Switzerland; 348 physicians responded to the invitation to participate.
Participating physicians received financial compensation.
Statistical Analysis
Student’s t test was applied to compare mean values of patient numbers seen by physicians, by
country and specialty (Germany vs US; cardiologists vs oncologists). A comparison of patients
undergoing IVD testing between countries and specialties was performed with a χ2 test (with 3
degrees of freedom) after recalculating the number of patients by weighted average. The corre-
lation between the replies regarding value of IVD in clinical practice and perceived costs was
estimated with the Spearman’s rank correlation coefficient. A Likert Scale (1 = lowest impor-
tance, 5 = highest importance) was used for the assessment of the relative importance of IVD
IVD Testing in Medical Practice: A Status Report
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subtypes during the initial patient work up phase. All statistical analyses were performed using
SAS version 9.4 (SAS Institute Inc, Cary, NC, US).
Results
Stage 1
IVD Spending as a Percentage of Total HCE. The literature research revealed that
healthcare spending on IVDs (defined as payments to clinical laboratories for testing services)
represents approximately 2.3% of all healthcare spending in the US (S1 Table). In Germany,
1.4% of public healthcare expenditure is used for IVD (S1 Table; Fig 2A). Although govern-
ment spending on IVD testing is well documented, private sector spending is not systematically
tracked on an annual basis, thus fewer data resources are available.
A retrospective analysis from 1993 through 2013 revealed that IVD spending in the US has
grown at an annual rate of 5.3% from US$30 billion in 1998 to an estimated US$67 billion in
2013. In Germany, spending on IVD has grown at a more modest annual rate of 3.1% since
1993, reaching US$ 4.5 billion in 2013. Overall, this has resulted in a relatively consistent HCE
on IVD testing in Germany, whereas a slight decline of 0.2% was observed in the US (Fig 2B).
Stage 2
IVD Use for Patients and Clinical Decision-Making. A total of 40 oncologists and 39
cardiologists participated in physician interviews. On average, 93 patients were seen per week
by oncologists and cardiologists in the US and Germany. Significantly more patients were
Fig 2. (A) Percentage of HCE on IVD in 2013 and (B) evolution of HCE on IVD 1993–2013.HCE, healthcare expenditure; IVD, in vitro diagnostics; $ B,
US$ billion.
doi:10.1371/journal.pone.0149856.g002
IVD Testing in Medical Practice: A Status Report
PLOS ONE | DOI:10.1371/journal.pone.0149856 March 4, 2016 7 / 16
treated by physicians in the US compared with Germany (p = 0.005). A comparable number of
patients underwent IVD testing in the US (74%) and Germany (76%) (p = 0.119; average 75%).
Overall, IVD testing was used in 88%, 77%, and 72% of patients for initial diagnosis, treatment
monitoring, and follow-up, respectively.
Significantly more oncology patients underwent IVD testing than cardiology patients (92%
vs 60%, respectively; p<0.0001) in both, the US (p<0.0001) and Germany (p<0.0001)
(Table 2). Overall, 75% of patients underwent IVD testing across both disciplines, testing that
led to a substantial clinical decision in 66% of these patients (Table 2).
IVD Subtype Use and Rated Subtype Importance
During the initial work-up phase, on average physicians used clinical chemistry and hematol-
ogy assessments in nearly 100% of patients, followed by immunology (86%). Basic and
Advanced Tissue Staining as well as molecular diagnostics was used in approximately half of
patients during the initial work-up phase. The average rating of IVD subtype importance corre-
sponded with its usage (S1 Fig). Detailed information about country- and specialty-related
IVD usage and rated importance is displayed in S2 Table.
Table 2. Number of Patients Receiving IVD Testing per Week and General Use of IVD Testing During Different Phases of Care.
Patients treated with IVD General use of IVD (%)
Country Specialty Setting Mean No. of
patients/week
Patients with
IVD testing (%)
Clinical decisions
affected by IVD (%)
Initial
diagnosis
Treatment
monitoring
Post-treatment
monitoring
US
Oncologist Total 62 91 58 95 95 79
Private 87 94 62 97 97 81
Hospital 45 88 54 92 92 76
Cardiologist Total 86 62 68 86 52a 52a
Private 99 42 59 79 44a 44a
Hospital 74 80 76 93 61a 61a
Average US 74 74 64 90 71 64
Germany
Oncologist Total 114 92 63 100 94 87
Private 95 88 58 99 92 77
Hospital 133 96 67 100 96 95
Cardiologist Total 112 59 71 75 68a 68a
Private 175 35 64 57 51a 51a
Hospital 95 92 80 99 90a 90a
Average Germany 113 76 67 87 81 78
Overall
Average oncologists 88 92 62 97 94 84
Average cardiologists 99 60 70 82 61a 61a
Average Overall (%) 75 66 88 77 72
Average Overall (in No. of
patients/week)
93 71 61
IVD, in vitro diagnostics. aFor cardiologists, only one question was asked on treatment monitoring and post-treatment monitoring.
doi:10.1371/journal.pone.0149856.t002
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Stage 3
Actual and Perceived Spending of IVD on HCE. Our analysis yielded a discrepancy
between the actual amount of IVD on HCE (2.3% in the US; 1.4% in Germany) and the per-
ceived amount of HCE by physicians. Throughout all specializations and irrespective of coun-
try, physicians tended to overestimate IVD-related monetary expenditure; this was most
pronounced among US cardiologists. In total, 81% of physicians estimated IVD expenditure to
be>5% of the total HCE.19% rated spending to be 0–4% (p<0.001) (Table 3).
Assessment of Appropriateness of IVD Costs on Overall HCE. After disclosure of the
actual proportion of HCE incurred by IVD testing (2.3% and 1.4% for the US and Germany,
respectively), 92% of all physicians rated the current IVD expenditure as either appropriate or
too low and 7% as too high (p<0.0001). No major differences were observed within countries
(Spearman’s correlation coefficient 0.291 for Germany, 0.003 for US) or specialization (Spear-
man’s correlation coefficient 0.118 for cardiology, 0.031 for oncology).
On a more granular level, 64% of physicians rated current IVD spending as appropriate;
28% of physicians assessed this spending as too low. 8% of the latter believed that innovative
assays deserve to command a higher price, even if total healthcare spend were to increase,
while 20% of the latter that innovative assays deserve a higher price but cost cuts would need to
be made in other segments of the healthcare value chain. Among the remaining 8% who rated
the current spending as too high, 5% believed that IVD savings should be added to other seg-
ments of the healthcare value chain.
Association Between Impact of IVD on Clinical Decisions and Perceived Cost Contribu-
tion. Physicians who rated the impact of IVD testing as rather low also believed that the asso-
ciated cost of such procedures was low. Conversely, physicians who rated the value of IVD
testing as high considered it to be more expensive (Spearman’s rank correlation coefficient
0.28617; p0.0001). For example, 26.7% of physicians who based>85% of their clinical deci-
sions on IVDs estimated the cost impact of IVDs at over 20% of the overall HCE (Table 4).
Physicians’ Expectations of IVDMarkers. Regarding the prospective development of new
IVD markers, 53% of physicians believed that IVD tests would need to demonstrate additional
clinical evidence of improved patient outcomes (p<0.0001 vs other criteria), 29% stated that
IVDs must provide health economic benefits plus evidence for improved patient outcome,
whereas only 8% of physicians selected health economic benefits to be the exclusive purchasing
factor. Overall, a significant proportion of physicians (83%) asked either for additional clinical
Table 3. Physicians’ estimation of IVD expenditure as a proportion of total HCE.
IVD expenditure, % of total HCE
Country 0–4% 5–10% 11–20% >20%
Germany, % physicians
Oncologist 20.0 43.3 20.0 16.7
Cardiologist 17.6 49.0 25.5 7.8
Total 18.5 46.9 23.5 11.1
US, % physicians
Oncologist 22.5 31.0 32.4 14.1
Cardiologist 14.0 38.0 26.0 22.0
Total 19.0 33.9 29.8 17.4
Overall 18.8 39.1 27.2 14.9
HCE, healthcare expenditure; IVD, in vitro diagnostic.
doi:10.1371/journal.pone.0149856.t003
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data or combined clinical and health economic data. Thus, these combined health economic
and outcomes benefits were more frequently requested than the sole provision of a diagnosis
(p<0.0001), indicating that the latter will be insufficient to cater for the future demand of
physicians.
Discussion
To our knowledge this is the first comprehensive analysis to investigate the relationship
between the value of IVDs and their associated cost in two major developed markets. Such an
analysis is particularly important as recognition and reimbursement levels for IVDs have
decreased significantly within the last 15 years [32]. Assessing the IVD utility–cost ratio is
therefore important in raising awareness of IVDs as a cost-efficient tool for patient manage-
ment. The present study has revealed at least four important findings:
1. The actual IVD spend as a part of overall HCE is low compared with other segments of the
health value chain, accounting for 2.3% and 1.4% in the US and Germany, respectively.
2. IVD testing guides approximately 66% of clinical decisions.
3. Physicians overrate the costs of IVD as a proportion of HCE.
4. Physicians demand diagnostic tests that show both clinical utility and cost-effectiveness.
1. Our investigations revealed that the HCE on IVD in the US and Germany is 2.3% and
1.4%. This is in line with the statement from the Lewin Group report, concluding that diagnos-
tics account for<5% of hospital costs and about 1.6% of all Medicare costs [26]. This cost is
rather low when compared with other segments of the medical value chain, such as pharma-
ceuticals and medical aids, which in Germany accounted for 15% and 5%, respectively, of pub-
lic HCE in 2013 [29]. Pharmaceutical spending on prescription medicines and over-the-
counter products as a proportion of the overall HCE in 2013 was estimated to be 11.9% in the
US and 17.5% in Canada [33].
As the percentage spent on IVDs relative to total HCE has remained fairly stable over the
last 20 years, the results of the present study indicate that IVDs have contributed to the growth
of the HCE at a constant low level (Fig 2). However, despite continuous discussion about cost
containment, it must not be forgotten that newer predictive companion diagnostics are eco-
nomically favorable. They allow patients who will benefit from a specific treatment to be identi-
fied and treated, while those who will not respond do not incur the cost for ineffective
Table 4. Relationship between percentage of clinical decisions based on IVD testing and perceived HCE on IVDs by physicians.
Clinical decisions based on IVD Perceived HCE on IVD
0–4% 5–10% 11–20% >20%
<20% 34.7%*** 40.8%*** 16.3%** 8.2%*
20–44% 19.7%** 44.3%*** 19.7%** 16.4%**
45–64% 7.7%* 36.5%*** 40.4%*** 15.4%**
65–85% 8.3%* 41.7%*** 33.3%*** 16.7%**
>85% 13.3%* 20.0%** 40.0%*** 26.7%**
*0–14.9%
**15–29.9%
***30–44.9%
HCE, healthcare expenditure; IVD, in vitro diagnostic.
doi:10.1371/journal.pone.0149856.t004
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treatment and management of possible side effects. Indeed, evidence exists for a high cost–ben-
efit ratio for identifying patients with KRAS and BRAF wild-type metastatic colorectal cancer
suitable for treatment with cetuximab and those with HER2-positive breast carcinomas who
will respond to trastuzumab [34, 35]. Furthermore, IVD-based screening programs may allow
a reduction in the number of expensive late-stage treatments through earlier interventions [8].
2. The present study confirms the widespread belief that IVDs play an important role in
clinical practice, as they influence 66% of clinical decision-making. This verifies the statement
from the Lewin Group, which reported this number to be between 60–70% [26], which was a
central aim of our study. Our investigation shows that clinical chemistry and hematology
assessments play a pivotal role for clinical decision making in the initial patient work-up phase.
This holds true for both the cardiology and oncology disease areas. Major differences in the use
of molecular testing between the oncology and cardiology settings illustrates the excellent prog-
ress made in the field of personalized healthcare in cancer management but concerns remain
over the low use of molecular testing in the cardiology field. Not surprisingly caution regarding
the future of hypertension pharmacogenetics is warranted in various studies [36].
The strong influence of IVD on clinical decisions also underlines the responsibility of diag-
nostic laboratories and companies to physicians and patients. The manufacturers of IVD prod-
ucts play an important role in the reduction of laboratory errors by ensuring the highest
possible safety and efficacy of their products [37]. Despite that fact that pre-analytical and
post-analytical steps are more error prone than the analytical phase and errors due to analytical
problems have been significantly reduced over the last two decades, laboratory errors are
known to have a serious impact on patients and their safety [38,39].
While there has been substantial progress in reducing errors associated with IVD testing,
additional challenges in the reduction of diagnostic errors and hence patient safety remain to
be addressed [40,41]. In fact, the frequency of diagnostic errors related to IVD may still be as
high as one out of 330 tests [38]. A recent publication from the US Institute of Medicine
addresses this challenge with eight goals for improving diagnosis [40].
3. In the present study, IVD costs were generally overestimated by physicians. This might be
triggered by the general belief of IVD overutilization, which has reported to be between 10–
50% [42]. However, a recent meta-analysis suggests that IVD underutilization is more preva-
lent than overutilization (44.8% vs. 20.6%) [43]. Interestingly is also the fact that there were
four times as many studies found on over- compared to underutilization during the assessed
15-year period and, despite in-depth literature research, only 42 studies finally matched the cri-
teria for review, indicating a poor level of evidence on inappropriate use of IVD testing [43].
Root causes for IVD over- and underutilization are summarized in the causal-loop diagram
shown in Fig 3.
Recently, the American Board of Internal Medicine has launched the “Choosing Wisely”
initiative [44], which aims to identify tests of little clinical value with potential for over-diagno-
sis [24]. The Swiss Society of Internal Medicine launched a similar campaign in 2014 called
“Smarter Medicine” [45].
Despite initial overestimation of IVD expenditure in the present analysis, most physicians
rated the actual IVD cost as appropriate or too low, clearly demonstrating a low awareness of
price structures among healthcare professionals. In a French study investigating cost awareness
of overall hospital expenditure among physicians, only 29% of their overall ratings were within
50% of the true costs [46]. In another survey, only 19% of general practitioners estimated the
true costs of laboratory and radiology tests in hospitals to be within 25% of the actual range
[47]. This is in line with the present study results, which indicate that only 19% of physicians
surveyed correctly estimated actual IVD costs.
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4. The last finding of this analysis is that the mere supply of diagnostic tests will not be suffi-
cient for physicians in the future, because evidence of accuracy does not automatically transfer
to evidence of efficiency [48]. The present study has shown that>50% of all physicians
demand proven clinical utility. These results reflect those of a study in which service provision
(defined as the provision of validated treatment algorithms) was rated as a significantly stron-
ger purchasing factor than technical preciseness [49]. There is evidence to suggest that physi-
cians are reluctant to use diagnostic tools when a test result cannot be sufficiently translated
into clinical actions [50]. Medical value in terms of clinical utility studies is able to close this
gap by demonstrating improved patient outcomes by either decreasing triage time [51] or
appropriate choice of treatment (companion diagnostics) [52].
The results of the present study furthermore demonstrate that 29% of all physicians demand
new IVD markers with health economic benefits. Although pharmaceutical companies incor-
porated the concept of economic value decades ago, vendors of IVDs still see themselves pri-
marily as providers of accurate technical equipment. This results in limited awareness of the
economic value of IVDs, neglecting the fact that regular testing can fundamentally reduce
healthcare costs, especially over the long term. In the US alone, US$1.3 billion could have been
Fig 3. Causal loop diagram displaying the root causes for over- and under-utilization of IVD testing. Key drivers displayed in boxes; antecedents
and secondary drivers displayed as plain text. IVD, in vitro diagnostic;!(+), positive causal links amplifying the behavior of target variable.
doi:10.1371/journal.pone.0149856.g003
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saved in 2004 if half of the patients with atrial fibrillation in routine medical care were opti-
mally treated with oral anticoagulation [53].
Limitations
This analysis has several limitations. The literature review was based on available public
sources. As a result of a lack of some reference points, calculations and assumptions were nec-
essary to fill gaps, which can lead to deviations from the actual spending. In Germany, the IVD
cost as a percentage of HCE was calculated based on public HCE only, whereas total HCE was
assessed in the US. An additional problem was the absence of a clear definition of “healthcare
spending”. Consequently, associated costs may differ between the US and Germany. The sur-
vey included a relatively small sample size of interviewed physicians and there is a need for val-
idation of the result using a larger sample base. In addition, the study was conducted for two
developed markets only and thus validity of the results for the rest of the world remains to be
proven.
Conclusions
IVDs are an indispensable tool in clinical practice as they govern approximately 66% of clinical
decision-making while accounting for approximately 2.3% and 1.4% of healthcare spending in
the US and Germany, respectively. Although the presumed HCE on IVDs is generally overesti-
mated by the majority of physicians, actual costs were considered as appropriate. IVDs can be
regarded a cost-effective measure to maximize treatment outcomes. When used with estab-
lished diagnostic algorithms, IVD testing can reduce direct and indirect healthcare costs [24],
generate better clinical outcomes [54], and thus create Medical Value [49].
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